To help increase the understanding of PHN and its management with Versatis^®, we are pleased to offer a range of materials that you and your patients may find useful.

• Professional resources for you

  Please find below a selection of materials and resources which may help give a greater understanding of Versatis^® and how 5% lidocaine medicated plaster has been of benefit to more than 18 million patients worldwide.⁵

  • Learn more about Versatis^®

    Please find below some downloads of background information, which you may find helpful in the treatment of PHN and the use of Versatis^®.

    • Versatis^® SmPC
      Clicking on this link will bring you to a 3rd party website. Grunenthal Pharma does not accept responsibility for the information contained on this website
    • 4-year study of efficacy and tolerability - Sabatowski et al 2012
    • Versatis^®fact sheet
    • Versatis^®'How to apply'

  • Sign up for our services

    If you would like to receive product information and services from Grünenthal within your country, please subscribe by completing the form below.

    Personal details

    First name Last name Email Speciality ... Pain Specialist Neurologist Rheumatologist Orthopedist / Traumatologist GP Physiotherapist Internal Medicine Oncologist Anesthesiologist Geriatrician Rehab Medicine Palliative Care Nurse Retail Pharmacist Hospital Pharmacist Other<

    Address

    Please select ... Afghanistan Åland islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua And Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia And Herzegowina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic Of The Cook Islands Costa Rica Cote D'Ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Heard Island And Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic Of Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakstan Kenya Kiribati Korea, Democratic People''s Republic Of Korea, Republic Of Kuwait Kyrgyzstan Lao People''s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macau Macedonia, The Former Yugoslav Republic Of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States Of Moldova, Republic Of Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts And Nevis Saint Lucia Saint Pierre And Miquelon Saint Vincent And The Grenadines Samoa San Marino Sao Tome And Principe Saudi Arabia Senegal Serbia and Montenegro Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia And The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard And Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province Of China Tajikistan Tanzania, United Republic Of Thailand Timor Leste Togo Tokelau Tonga Trinidad And Tobago Tunisia Turkey Turkmenistan Turks And Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis And Futuna Western Sahara Yemen Yugoslavia Zambia Zimbabwe

    Type of address

    Office Hospital

    In providing my contact details I understand that my data will be shared within the Grünenthal Group. Further information about the use of the data collected is provided within the privacy policy statement
    
    By ticking this box I also give permission for Grünenthal Group to use my contact information to inform me of their services and prescription medicines from time to time.

    Privacy Statement Grunenthal GmbH

  • Congresses and events

    A review of the IASP 14th World Congress on Pain 2012, Milan

    Grünenthal was delighted to sponsor a symposium at the IASP Congress, entitled, 'Tackling the Burden of Patients Suffering from Postherpetic Neuralgia - Long-term Treatment with Topical 5% Lidocaine Medicated Plaster'.

    Below are summaries of some of the presentations, along with additional supporting information for your reference.

    Presentation

    'Cognitive Functioning of Patients with Postherpetic Neuralgia: Topical Treatment May Reverse Cognitive Impairment Associated with Neuropathic Pain Symptoms'

    Presenter

    Dr G Pickering.

    

    Presentation

    'A Topical Approach to Chronic Pain: Up to 4 Years Treatment with 5% Lidocaine Medicated Plasters in Neuropathic Pain Patients Suffering from PHN'

    Presenter

    Prof G Wasner.

    

  • Contact us

    For further information, click here.
    
    GeneralenquiresIE@grunenthal.com Phone: +44 (0) 870 351 8960
    
    Fax: + 353 (0) 1 466 0793
    
    Grünenthal Pharma Ltd., Dublin, Ireland
    www.grunenthal.ie

    Adverse event reporting, click here
    
    Medical.InformationIE@grunenthal.com
    

• Resources for your patients

  Here is a range of materials that can be shared with your patients to help them understand their condition and to get the most from their treatment with Versatis^®.

  Versatis^®'How to apply'

  Patient & physician

  Application to affected area

  Application to face

  Water / swimming usage

• FAQ's

  The information on this website cannot, and should not, replace the conversation between the healthcare professional and the patient. Versatis^® is a prescription only medication. Only the healthcare professional can decide which treatment option is the most appropriate for the patient. Individual treatment results with Versatis^® may vary.

  Frequently asked questions about using Versatis^® for the treatment of PHN:

  When to use Versatis^®?

  Versatis^® is indicated for the symptomatic relief of neuropathic pain associated with previous herpes zoster infection(postherpetic neuralgia, PHN) in adults. ¹

  What does "Works where it hurts" mean?

  The Versatis^® plaster is applied only to the directly affected painful area - which is the area where the active substance lidocaine is released and can penetrate through the skin. ¹ It reaches the damaged nerves under the skin where it blocks abnormal sodium channels. This analgesic effect results in the patient experiencing pain relief.²

  What are typical symptoms of post-herpetic neuralgia (PHN)?

  Post-herpetic neuralgia is a type of localised neuropathic pain. Many patients report burning, stabbing or shooting pain. ^2,9

  How effective is Versatis^®?

  Clinical data indicates that Versatis^® achieves a 62% responder rate with over 80% of responding patients experiencing pain relief within the first two weeks.^2,3 Four-year clinical data confirms the sustained long-term efficacy of Versatis.^{® 4}

  How quickly can patients expect to experience pain relief with Versatis^®?

  Of those patients who respond to Versatis^®, over 80% experience pain relief within the first two weeks. ² Generally, it may take 2-4 weeks until Versatis^® shows optimal effect. If there has been no response to Versatis after this period, treatment should be discontinued. ¹

  How long should Versatis^® be in contact with the skin?

  It is important that Versatis^® is in contact with the skin for a maximum of 12 hours in any 24 hour period. However, due to the mechanism of action which releases lidocaine and blocks abnormal sodium channels of the damaged nerves, pain relief effect is maintained for the 24 hour period. ^1,2

  Should Versatis^® be used during the day or at night?

  Both are viable options.¹ Patients should choose the option that is best for them. The plaster has the additional advantage of offering a physical barrier protecting the sensitive skin area against a painful stimulus. This stimulus can be a shirt, a belt or even the touch of other people. This is why some people prefer to wear Versatis^® during the day time. On the other hand, some patients prefer to use Versatis^® overnight due to aesthetic reasons - for example when the painful area is in a very obvious place like the face.

  Can the Versatis^® plasters be reused?

  No, each Versatis^® plaster is intended for single use only.¹

  Can Versatis^® be used on any part of the body?

  Versatis^® can be used on the body on areas of pain after the shingles rash has healed. It should not be applied to mucous membranes, on injured skin, open wounds or areas of ongoing shingles infection. Versatis^® can be used on the face, although not on, or near, the eyes or mouth. ¹

  Does using Versatis^® restrict a patient's everyday activities?

  Patients can pursue most of their everyday activities whilst using Versatis^®, including driving or operating machinery. However, direct contact with water should be avoided.¹
  Because Versatis^® is a topical treatment with minimal absorption, it has a low rate of systemic side effects and is easy for patients to use. ¹

  Is Versatis^® recommended as a first-line treatment option?

  Yes, Versatis^® is indeed recommended as a first-line treatment option for post-herpetic neuralgia in the elderly by the European Federation of Neurological Societies (EFNS) Guidelines. ⁶

  How many patients have already benefited from this therapeutic principle?

  It has been estimated that this targeted treatment option has been used in more than 18 million patients worldwide. ⁵